XPOVIO(R) (selinexor) Now Funded in Quebec

Impact · against what's priced in

The funding of XPOVIO in Quebec provides a positive catalyst for revenue growth through expanded patient access, though the scale is limited to a single regional market. PharmaEssentia's mention in the context of a separate BESREMi agreement is a reminder of existing partnerships rather than a new driver.

PXS+0.20

No priced-in read yet

In context

The public funding of XPOVIO in Quebec for multiple myeloma increases patient access and potential revenue in a key regional market.

Read from the article alone

• healthcare
• PXS
• X
• biopharma
• canada
• cancer treatment
• drug funding
• multiple myeloma
• pharmaceuticals
• quebec

Search tags